NCT06530966View on ClinicalTrials.gov

Phase I Study of ICP-332 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

December 25, 2024

Study Completion Date

December 25, 2024

Conditions
Healthy Subjects
Interventions
DRUG

ICP-332 Tablets

Eligible patients will receive ICP-332 tablets orally as per the protocol

DRUG

ICP-332 Placebo Tablets

Eligible patients will receive ICP-332 placebo tablets orally as per the protocol

Trial Locations (1)

21201

RECRUITING

Pharmaron CPC Inc., Baltimore

Sponsors
All Listed Sponsors
lead

InnoCare Pharma Inc.

INDUSTRY

NCT06530966 - Phase I Study of ICP-332 in Healthy Subjects | Biotech Hunter | Biotech Hunter